Drug intelligence / Profile preview

ciprofloxacin + rifaximin

Development stage: Unknown
Lead developer: Salix Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

Ciprofloxacin + rifaximin is a combination antibiotic therapy primarily used for treating chronic active refractory pouchitis. Ciprofloxacin is a fluoroquinolone antibiotic that treats a wide variety of infections, while rifaximin is a poorly absorbed rifamycin derivative. This combination has shown effectiveness in cases where other treatments have failed, with studies demonstrating significant improvement in patients with chronic active refractory pouchitis when treated with rifaximin 1g twice daily plus ciprofloxacin 500mg twice daily for two weeks.

Other names: rifaximin + ciprofloxacinciprofloxacin + rifaximinrifaximin-Assistance Publique - Hôpitaux de Paris-Crohn's disease

Targets

DNA gyraserpoB (DNA-directed RNA polymerase subunit beta)

Beyond the preview

Go deeper on ciprofloxacin + rifaximin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ciprofloxacin + rifaximin.

Explore the full profile